...premiums larger than 100%. The two smallest premiums, in Principia’s acquisition by Sanofi (Euronext:SAN; NASDAQ:SNY) and Dermira’s...

...raised $560.9 million in a follow-on offering through the sale of 5.2 million shares at $108.Dermira...
...develop therapies for chronic inflammatory diseases. The start-up was co-founded by a trio of former Dermira Inc....
...autoimmune and dermatology company, joins as SVP, product development. Eli Lilly and Co. (NYSE:LLY) acquired Dermira...

...TPEx:6497; NASDAQ:ASLN) hired Kenneth Kobayashi as CMO. He was a senior medical director at the Dermira Inc....

...in March. SutroVax Inc. hired Andrew Guggenhime as CFO and CBO. He was CFO of Dermira Inc....

...year’s only other billion-plus-dollar M&A deal in the sector was the buyout of dermatology company Dermira Inc....
...Challenger” ; “Only Biopharma to Make Offer After Outreach” ). Both the Forty Seven and Dermira...

...it would acquire Dermira for about $1.1 billion in cash at a 117% premium to Dermira’s...
...Dermira’s stock continued to climb and the company continued to reach out to other suitors. Dermira...
...February, Dermira granted Almirall S.A. (Madrid:ALM) an option to exclusively sub-license lebrikizumab in Europe. After Dermira...

...Via its $1.1 billion takeout of Dermira on Friday, Eli Lilly added to its late-stage pipeline...
...premium to Dermira’s last 60-day volume-weighted average price. Investors might be expecting a rival bid. Dermira...
...valuation by 66% in a day (see “Dermira Plummets After Phase III Acne Failure” ). Dermira’s...

...Regeneron gained $15.40 to $341.79 on Friday. Another company with a potential Dupixent competitor, Dermira Inc....
...more convenient than that of Dupixent. Lebrikizumab prevents IL-13RA1/IL-4R heterodimer formation and downstream signaling (see "Dermira...
...ANB020) REGN3500, SAR440340 Dupixent (Brand), SAR231893 (Compound #), REGN668 (Compound #), dupilumab (Generic), Dupixent (Informal) AnaptysBio Inc. Regeneron Pharmaceuticals Inc. Sanofi Dermira Inc. Interleukin-33...

...support to the idea that its atopic dermatitis therapy could compete with Dupixent on dosing. Dermira Inc....
...Severity Index (EASI), at week 16 vs. placebo in adults with moderate-to-severe atopic dermatitis (see “Dermira...
...every 4 weeks. Thursday’s presentation at the Fall Clinical Dermatology Conference in Las Vegas drove Dermira...

...NASDAQ:CBMG) 3/22/19 $17.5 $324.9 $317.8 -2% Oragenics Inc. (NYSE-M:OGEN) (A) 3/22/19 $12.5 NA $22.6 NA Dermira Inc....